000130435 001__ 130435
000130435 005__ 20240125162930.0
000130435 0247_ $$2doi$$a10.1038/s41391-018-0074-5
000130435 0248_ $$2sideral$$a108191
000130435 037__ $$aART-2018-108191
000130435 041__ $$aeng
000130435 100__ $$0(orcid)0000-0003-0178-4567$$aBorque-Fernando, Á.$$uUniversidad de Zaragoza
000130435 245__ $$aRole of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance
000130435 260__ $$c2018
000130435 5060_ $$aAccess copy available to the general public$$fUnrestricted
000130435 5203_ $$aBackground: Management of active surveillance (AS) in low-risk prostate cancer (PCa) patients could be improved with new biomarkers, such as the 4Kscore test. We analyze its ability to predict tumor reclassification by upgrading at the confirmatory biopsy at 6 months. Methods: Observational, prospective, blinded, and non-randomized study, within the Spanish National Registry on AS (AEU/PIEM/2014/0001; NCT02865330) with 181 patients included after initial Bx and inclusion criteria: PSA =10 ng/mL, cT1c-T2a, Grade group 1, =2 cores, and =5 mm/50% length core involved. Central pathological review of initial and confirmatory Bx was performed on all biopsy specimens. Plasma was collected 6 months after initial Bx and just before confirmatory Bx to determine 4Kscore result. In order to predict reclassification defined as Grade group =2, we analyzed 4Kscore, percent free to total (%f/t) PSA ratio, prostate volume, PSA density, family history, body mass index, initial Bx, total cores, initial Bx positive cores, initial Bx % of positive cores, initial Bx maximum cancer core length and initial Bx cancer % involvement. Wilcoxon rank-sum test, non-parametric trend test or Fisher’s exact test, as appropriate established differences between groups of reclassification. Results: A total of 137 patients met inclusion criteria. Eighteen patients (13.1%) were reclassified at confirmatory Bx. The %f/t PSA ratio and 4Kscore showed differences between the groups of reclassification (Yes/No). Using 7.5% as cutoff for the 4Kscore, we found a sensitivity of 89% and a specificity of 29%, with no reclassifications to Grade group 3 for patients with 4Kscore below 7.5% and 2 (6%) missed Grade group 2 reclassified patients. Using this threshold value there is a biopsy reduction of 27%. Additionally, 4Kscore was also associated with changes in tumor volume. Conclusions: Our preliminary findings suggest that the 4Kscore may be a useful tool in the decision-making process to perform a confirmatory Bx in active surveillance management.
000130435 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000130435 590__ $$a4.6$$b2018
000130435 591__ $$aUROLOGY & NEPHROLOGY$$b10 / 79 = 0.127$$c2018$$dQ1$$eT1
000130435 591__ $$aONCOLOGY$$b63 / 228 = 0.276$$c2018$$dQ2$$eT1
000130435 592__ $$a2.2$$b2018
000130435 593__ $$aCancer Research$$c2018$$dQ1
000130435 593__ $$aUrology$$c2018$$dQ1
000130435 593__ $$aOncology$$c2018$$dQ1
000130435 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000130435 700__ $$aRubio-Briones, J.
000130435 700__ $$0(orcid)0000-0002-3007-302X$$aEsteban, L.M.
000130435 700__ $$aDong, Y.
000130435 700__ $$aCalatrava, A.
000130435 700__ $$aGómez-Ferrer, Á.
000130435 700__ $$aGómez-Gómez, E.
000130435 700__ $$0(orcid)0000-0002-5629-7646$$aGil Fabra, J.M.$$uUniversidad de Zaragoza
000130435 700__ $$aRodríguez-García, N.
000130435 700__ $$aLópez González, P.Á.
000130435 700__ $$aGarcía-Rodríguez, J.
000130435 700__ $$aRodrigo-Aliaga, M.
000130435 700__ $$aHerrera-Imbroda, B.
000130435 700__ $$aSoto-Villalba, J.
000130435 700__ $$aMartínez-Breijo, S.
000130435 700__ $$aHernández-Cañas, V.
000130435 700__ $$aSoto-Poveda, A.M.
000130435 700__ $$aSánchez-Rodríguez, C.
000130435 700__ $$aCarrillo-George, C.
000130435 700__ $$aHernández-Martínez, Y.E.
000130435 700__ $$aOkrongly, D.
000130435 7102_ $$11004$$2817$$aUniversidad de Zaragoza$$bDpto. Cirugía,Ginecol.Obstetr.$$cÁrea Urología
000130435 773__ $$g22 (2018), 84–90$$pProstate cancer prostatic dis.$$tPROSTATE CANCER AND PROSTATIC DISEASES$$x1365-7852
000130435 8564_ $$s326700$$uhttps://zaguan.unizar.es/record/130435/files/texto_completo.pdf$$yPostprint
000130435 8564_ $$s1057343$$uhttps://zaguan.unizar.es/record/130435/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000130435 909CO $$ooai:zaguan.unizar.es:130435$$particulos$$pdriver
000130435 951__ $$a2024-01-25-15:10:28
000130435 980__ $$aARTICLE